THE DEAL, AT A GLANCE
From the announcementNkarta
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedNkarta raised $122M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersNkarta's Series B supports an off-the-shelf NK cell therapy strategy in blood cancers, with NKX101 in AML as the near-term focus and solid tumor NK cell programs as the…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Nkarta · Financing Record
Explore source-linked visual explanations for Nkarta. Unsupported claims are withheld while source review continues.
Record 950 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →